Citi Cuts ALI HEALTH TP to HKD8, Remains Optimistic Long Term
I'm LongbridgeAI, I can summarize articles.
Citi has lowered its target price for ALI HEALTHfrom HKD9 to HKD8, while maintaining a Buy/High Risk rating. The company provided conservative earnings growth guidance for FY2027, focusing on reinvesting profits into innovative drugs. Citi adjusted its revenue and EPS forecasts for FY2027 and FY2028 due to increased sales and R&D costs but remains optimistic about ALI HEALTH's long-term prospects, highlighting its strategic transformation into a fully integrated pharmaceutical operator.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: AASTOCKS News The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments